Eribulin mesylate

Nat Rev Drug Discov. 2011 Mar;10(3):173-4. doi: 10.1038/nrd3389.
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Drug Approval
  • Ethers, Cyclic / chemistry
  • Ethers, Cyclic / pharmacology
  • Female
  • Furans / adverse effects
  • Furans / pharmacology
  • Furans / therapeutic use*
  • Humans
  • Ketones / adverse effects
  • Ketones / pharmacology
  • Ketones / therapeutic use*
  • Macrolides
  • Mesylates / adverse effects
  • Mesylates / pharmacology
  • Mesylates / therapeutic use*
  • Microtubules / drug effects
  • Neoplasm Metastasis

Substances

  • Antineoplastic Agents
  • Ethers, Cyclic
  • Furans
  • Ketones
  • Macrolides
  • Mesylates
  • halichondrin B
  • eribulin